The rapid and accurate diagnosis of symptomatic patients is the cornerstone of global strategies for TB control.
From specimen collection to actionable reporting, BD offers the right fit for your M. tuberculosis and other mycobacteria testing needs, as well as local training, service and technical support.
In response to WHO recommendations for the use of liquid culture systems for TB diagnosis in 2007, BD and FIND announced a pricing agreement to make BD MGIT liquid culture testing available to 39 high-burden, low-income countries. Furthermore, BD has responded to the threat of XDR-TB with expanded support of FIND and by developing new tools which enable the testing and reporting of existing and potentially new 2nd-line drugs on BD BACTEC™ MGIT™ 960.
We are dedicated to improving people’s health throughout the world.
|Learn about this BD Global Initiative (English) »|
|XDRTB.org - Spread the Story. Stop the disease - Sponsored by BD »|
|BD Diagnostics launches the BD MGIT™ TBc Identification Test in Africa and the European Union »|